Effect of a prostacyclin derivative (iloprost) on regional blood flow, sympathetic nerve activity, and baroreceptor reflex in the conscious rat

H Steinberg, OS Medvedev, FC Luft… - Journal of …, 1988 - journals.lww.com
H Steinberg, OS Medvedev, FC Luft, T Unger
Journal of cardiovascular pharmacology, 1988journals.lww.com
We have investigated the hemodynamic actions of iloprost, a stable prostacyclin derivative,
in conscious, chronically instrumented rats. Given intravenously by 10-min infusions at
doses ranging from 0.0375 to 4 [mu] g/min, iloprost lowered mean arterial blood pressure in
a dose-dependent and reversible fashion. The effects on blood pressure were accompanied
by increases in heart rate (HR); splanchnic nerve activity (SpNA, direct recording); and
mesenteric, renal, and hindlimb blood flow (Doppler probes). Doses below the depressor …
Abstract
We have investigated the hemodynamic actions of iloprost, a stable prostacyclin derivative, in conscious, chronically instrumented rats. Given intravenously by 10-min infusions at doses ranging from 0.0375 to 4 [mu] g/min, iloprost lowered mean arterial blood pressure in a dose-dependent and reversible fashion. The effects on blood pressure were accompanied by increases in heart rate (HR); splanchnic nerve activity (SpNA, direct recording); and mesenteric, renal, and hindlimb blood flow (Doppler probes). Doses below the depressor threshold already reduced mesenteric and hindlimb vascular resistance without affecting HR. The reduction of hindlimb resistance outlasted the iloprost infusion period. Chronic sinoaortic deafferentation (SAD) almost abolished the tachycardic reflex responses to intravenous sodium nitroprusside. The reflex increases in SpNA to intravenous iloprost were also largely prevented in SAD animals, but the tachycardic effects of iloprost persisted. In addition, neither [beta] 1-adrenoceptor blockade alone nor complete cardiac autonomic blockade prevented the heart rate responses to iloprost. Our results show that iloprost is a potent vasodilator that preferentially reduces hindlimb vascular resistance. Low doses of the drug increase regional blood flow without affecting blood pressure or heart rate. The tachycardic effects at higher doses cannot be explained by baroreceptor reflex (BRR) activation alone; they instead suggest a direct action on the heart. The dissociation between vasodilator and depressor effects at low doses may contribute to the therapeutic benefit of the drug in the treatment of vascular disease.
Lippincott Williams & Wilkins